Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Phase III FIRE-4 study (AIO KRK-0114): Evaluation of first-line treatment efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC receiving the first cycle of treatment with chemotherapy only.
Authors
Sebastian Stintzing
Medical Department, Division of Hematology, Oncology, and Cancer Immunology (CCM), Charité Universitätsmedizin Berlin, Berlin, Germany;
Sebastian Stintzing , Ludwig Fischer von Weikersthal , Martin Fuchs , Florian Kaiser , Kathrin Heinrich , Dominik Paul Modest , Ralf-Dieter Hofheinz , Thomas Decker , Armin Gerger , Stefan Angermeier , Holger Rumpold , Andreas Dickhut , Leopold Öhler , Birgit Gruenberger , Dora Niedersuess-Beke , Matthias Sandmann , Thomas Winder , Joerg Trojan , Gerald Prager , Volker Heinemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02934529
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 100)
DOI
10.1200/JCO.2023.41.4_suppl.100
Abstract #
100
Poster Bd #
E17
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114).
First Author: Sebastian Stintzing
Poster
2017 ASCO Annual Meeting
Right-sided colorectal cancer (RC): Response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR).
First Author: Julian Walter Holch
Poster
2016 Gastrointestinal Cancers Symposium
Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.
First Author: Stefano Cascinu
Poster
2014 ASCO Annual Meeting
A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G).
First Author: Kentaro Yamazaki